Renal-Cell Carcinoma

Immune Checkpoint Inhibitor plus VEGFR Inhibitor Combo Outperforms Sunitinib in Renal-Cell Carcinoma

Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium

Page 2 of 2
Results 11 - 11 of 11

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive:

TOP Print Edition

TOP Weekly e‑Newsletter

I have reviewed and consent to the terms of TOP's Privacy Policy, and TOP has my permission to retain my information in its database, and to forward pertinent communications to me.